This white paper is based on a live web panel, hosted by ShareVault and the Biotechnology Industry Organization (BIO), discussing   what's exciting in cancer drug development versus what is not popular in licensing, and why.

For the live event, biotech licensing and pharmaceutical business development consultant Linda Pullan was joined by three panelists who are business development experts from a global pharmaceutical company, a leading academic cancer center, and a top business development consulting firm. The panelists discussed theories of cancer, favorite targets and modalities, the impact of reimbursement, deal types, and more.

In addition to complete written coverage of the panel discussion, the white paper, authored and edited by the panelists, provides fresh content: responses to questions received during the panel that were not answered due to time constraints.

If you are developing a cancer drug or working toward in- or out-licensing of a cancer drug, you will want to read these perspectives.

the white paper




ShareVault’s secure document sharing solution gives pharmaceutical and biotechnology  organizations the confidence to simply and securely share sensitive documents with third parties during due diligence, product development, technology transfers, fundraising, partnering, collaborative research and other activities that require the highest level of document security.

Compared to consumer-grade solutions, ShareVault virtual data rooms offer many features that give you control and document intelligence with the highest level of document-protection and monitoring available. Learn more.